Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
about
Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF.Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis.Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan.Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues.A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma.Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.Targeted therapy for metastatic renal cell cancer.Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy.Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.A late recurrence of renal cell carcinoma as pancreatic metastases: a rare disease.Prognostic stratification of renal cell carcinoma using a pathological triad of microvascular invasion, Fuhrman's grade and tumor size.Transcatheter arterial embolization with spherical embolic agent for pulmonary metastases from renal cell carcinoma.Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib.Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.Value of ablation therapy in the treatment of lung metastases.Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma.Expression pattern of autophagy-related markers in non-metastatic clear cell renal cell carcinoma: association with disease recurrence following radical nephrectomy.Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor.Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy.
P2860
Q30444037-0ECCAE53-6329-41CA-BB73-77EE74C2D370Q33398317-CB356D88-6135-4349-98DE-E0B7B76E6C8EQ33404146-285BB478-C23F-46B8-BD73-A3B42CE26240Q33410223-B26F3A39-190D-4D12-B43E-B313ED3284C7Q36072803-142DDA70-966E-4E3B-A8CD-6A0645EE81D0Q36958851-5ABED069-42D5-40B6-9D6B-20B01279FA70Q37041069-AD93376C-3B1E-43C0-B7C4-D964C468E4CCQ37279290-611ABFEF-D6D3-4750-8E60-C658D8B8BD48Q37758685-EE88E4ED-BD9D-492E-8F3A-425FDD361C0DQ38132624-77B739B2-2D5B-4F1F-9161-B481E6795A85Q39213121-7FD541B6-F0C1-4904-8D3C-6AD78CE2E6FEQ41361229-47D43AD3-C8ED-42D9-80F4-45703CC74A64Q41826731-1A193F50-94C3-47FD-AF7F-53B1D0402DBDQ44551818-ABF12B3A-A20F-4BE7-8DCA-88DF0F4E4B75Q44750309-5A1AC485-2A7C-4FE0-A3C7-86B26DCEED99Q45974727-B7166A81-FCCD-4423-A7CB-97E046D2DDC2Q47731587-AFACABEC-98D4-4EEF-AEC1-ECE0BCAC18B3Q48200047-31BC87AE-4BC3-4EC9-A1F9-9B4BD70743D3Q49116772-9AA9DF22-9494-4389-80AD-4AF446DE4342Q51763288-925A22A1-8998-4711-A427-187BBE657CF5Q52971058-32465C8C-116E-431F-9F0E-E55617B449E4Q53045089-F184D461-ACF5-49C0-BBE1-4BF504A28EFDQ53161865-AC59AE37-391D-45C6-BA69-831FA2FB343F
P2860
Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Present strategies in the trea ...... on molecular targeting agents.
@ast
Present strategies in the trea ...... on molecular targeting agents.
@en
type
label
Present strategies in the trea ...... on molecular targeting agents.
@ast
Present strategies in the trea ...... on molecular targeting agents.
@en
prefLabel
Present strategies in the trea ...... on molecular targeting agents.
@ast
Present strategies in the trea ...... on molecular targeting agents.
@en
P2093
P2860
P1433
P1476
Present strategies in the trea ...... on molecular targeting agents
@en
P2093
Clara Montagut
Joaquim Bellmunt
Pablo Maroto
Santiago Albiol
P2860
P304
P356
10.1111/J.1464-410X.2006.06589.X
P577
2006-12-01T00:00:00Z